Improved oral bioavailability of valsartan using proliposomes: design, characterization and in vivo pharmacokinetics.
The objective of our investigational work was to develop a proliposomal formulation to improve the oral bioavailability of valsartan. Proliposomes were formulated by thin film hydration technique using different ratios of phospholipids:drug:cholesterol. The prepared proliposomes were evaluated for vesicle size, encapsulation efficiency, morphological properties, in vitro drug release, in vitro permeability and in vivo pharmacokinetics. In vitro drug-release studies were performed in simulated gastric fluid (pH 1.2) and purified water using dialysis bag method. In vitro drug permeation was studied using parallel artificial membrane permeation assay (PAMPA), Caco-2 monolayer and everted rat intestinal perfusion techniques. In vivo pharmacokinetic studies were conducted in male Sprague Dawley (SD) rats. Among the proliposomal formulations, F-V was found to have the highest encapsulation efficiency of 95.6 ± 2.9% with a vesicle size of 364.1 ± 14.9 nm. The in vitro dissolution studies indicated an improved drug release from proliposomal formulation, F-V in comparison to pure drug suspension in both, purified water and pH 1.2 dissolution media after 12 h. Permeability across PAMPA, Caco-2 cell and everted rat intestinal perfusion studies were higher with F-V formulation as compared to pure drug. Following single oral administration of F-V formulation, a relative bioavailability of 202.36% was achieved as compared to pure valsartan.
a Graduate College of Biomedical Sciences, Western University of Health Sciences , Pomona , CA , USA .
Vijaykumar
V
Nekkanti
b Chicago College of Pharmacy, Midwestern University , Downers Grove , IL , USA , and.
Natarajan
N
Venkatesan
c College of Pharmacy, Western University of Health Sciences , Pomona , CA , USA.
Zhijun
Z
Wang
a Graduate College of Biomedical Sciences, Western University of Health Sciences , Pomona , CA , USA .|c College of Pharmacy, Western University of Health Sciences , Pomona , CA , USA.
Guru V
GV
Betageri
D000284:Administration, Oral; D000818:Animals; D001682:Biological Availability; D018938:Caco-2 Cells; D015195:Drug Design; D006801:Humans; D008081:Liposomes; D008297:Male; D011355:Prodrugs / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D051381:Rats; D017207:Rats, Sprague-Dawley; D000068756:Valsartan / Q000008:administration & dosage* / Q000493:pharmacokinetics*
D008081:Liposomes; D011355:Prodrugs; D000068756:Valsartan
Caco-2; PAMPA; dissolution; oral bioavailability; pharmacokinetics; proliposomes; valsartan